
Davide Lombardi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9927761/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. Journal of Clinical Oncology, 2016, 34, 1601-1610.	1.6	100
2	Familial breast cancer: characteristics and outcome of BRCA 1–2 positive and negative cases. BMC Cancer, 2005, 5, 70.	2.6	73
3	A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies. Breast Cancer Research, 2011, 13, R117.	5.0	30
4	New oral drugs in older patients: a review of idarubicin in elderly patients. Critical Reviews in Oncology/Hematology, 2004, 49, 153-163.	4.4	29
5	Ultrasound Microvascular Blood Flow Evaluation: A New Tool for the Management of Thyroid Nodule?. International Journal of Endocrinology, 2019, 2019, 1-6.	1.5	18
6	Continuous Infusion Fluorouracil in the Management of Advanced Breast Cancer: A Phase II Study. Tumori, 2000, 86, 42-45.	1.1	10
7	Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients. BMC Cancer, 2014, 14, 954.	2.6	9
8	Lapatinib-Based Therapy in Heavily Pretreated HER2-Positive Metastatic Breast Cancer: A Single Institution Experience. Tumori, 2012, 98, 33-38.	1.1	4
9	Ultrasound of benign thyroid nodules: A 120 months followâ€up study. Clinical Endocrinology, 2021, 94, 866-871.	2.4	4
10	Incidence of Palmar-Plantar Erythrodysesthesia in Pretreated and Unpretreated Patients Receiving Pegylated Liposomal Doxorubicin. Tumori, 2009, 95, 687-690.	1.1	3
11	Selecting for BRCA1 testing using a combination of homogeneous selection criteria and immunohistochemical characteristics of breast cancers. BMC Cancer, 2009, 9, 360.	2.6	3
12	Epirubicin and Docetaxel as Neoadjuvant Treatment of Locally Advanced Breast Cancer: A Phase II Study. Tumori, 2010, 96, 229-233.	1.1	3
13	Idarubicin. Tumori, 2002, 88, S73-S74.	1.1	2
14	Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies. Radiology and Oncology, 2013, 47, 57-62.	1.7	2
15	Epirubicin and docetaxel as neoadjuvant treatment of locally advanced breast cancer: a phase II study. Tumori, 2010, 96, 229-33.	1.1	2
16	KIR-HLA Functional Repertoire Influences Trastuzumab Efficiency in Patients With HER2-Positive Breast Cancer. Frontiers in Immunology, 2021, 12, 791958.	4.8	2